Nippon Shinyaku President Nakai (中井) said that the launch timing for the cell therapy product CAP-1002 had not been determined and revised down the full-year earnings forecast. At the same time, the company is pursuing earnings-structure reform with the aim of securing profits.
Nippon Shinyaku is reported to have said that the launch timing for the cell therapy product CAP-1002 has not been determined. Accordingly, the company's full-year earnings are expected to be revised downward.
The company has stated its policy of pursuing earnings-structure reform and indicated that it intends to secure profits through these efforts.
The focus of the news is the uncertainty surrounding the company's product launch timing, the resulting change in its earnings outlook, and the shift in management policy toward improving its earnings structure over the long term.
The timing of CAP-1002's clinical use and market launch remains undetermined, and the situation awaits further official announcements and updates in earnings briefings.